Vaginal Cancer – Pipeline Review, H2 2020

Global Markets Direct’s, ‘Vaginal Cancer – Pipeline Review, H2 2020’, provides an overview of the Vaginal Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Vaginal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Vaginal Cancer and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Vaginal Cancer

– The report reviews pipeline therapeutics for Vaginal Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Vaginal Cancer therapeutics and enlists all their major and minor projects

– The report assesses Vaginal Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Vaginal Cancer

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Vaginal Cancer

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Vaginal Cancer pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AstraZeneca Plc

Beijing Kangle Guardian Biotechnology Co Ltd

Beijing Recreation Guards Biotechnology Co Ltd

Beijing Shenzhou Cell Biotechnology Group Co Ltd

Bristol-Myers Squibb Co

Chengdu Institute of Biological Products Co Ltd

Eisai Co Ltd

F. Hoffmann-La Roche Ltd

Fujifilm Holdings Corp

Gilead Sciences Inc

ISA Pharmaceuticals BV

Merck & Co Inc

Merck KGaA

Ology Bioservices Inc

Ono Pharmaceutical Co Ltd

PDS Biotechnology Corp

Plexxikon Inc

Precigen Inc

Shanghai Bovax Biotechnology Co Ltd

Shanghai Zerun Biotechnology Co Ltd

SQZ Biotechnologies Co

Transgene SA

Turnstone Biologics Inc

Table of Contents

Table of Contents

Introduction

Vaginal Cancer- Overview

Vaginal Cancer- Therapeutics Development

Vaginal Cancer- Therapeutics Assessment

Vaginal Cancer- Companies Involved in Therapeutics Development

Vaginal Cancer- Drug Profiles

Vaginal Cancer- Dormant Projects

Vaginal Cancer- Discontinued Products

Vaginal Cancer- Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Vaginal Cancer, H2 2020

Number of Products under Development by Companies, H2 2020

Products under Development by Companies, H2 2020

Number of Products by Stage and Target, H2 2020

Number of Products by Stage and Mechanism of Action, H2 2020

Number of Products by Stage and Route of Administration, H2 2020

Number of Products by Stage and Molecule Type, H2 2020

Vaginal Cancer – Pipeline by AstraZeneca Plc, H2 2020

Vaginal Cancer – Pipeline by Beijing Kangle Guardian Biotechnology Co Ltd, H2 2020

Vaginal Cancer – Pipeline by Beijing Recreation Guards Biotechnology Co Ltd, H2 2020

Vaginal Cancer – Pipeline by Beijing Shenzhou Cell Biotechnology Group Co Ltd, H2 2020

Vaginal Cancer – Pipeline by Bristol-Myers Squibb Co, H2 2020

Vaginal Cancer – Pipeline by Chengdu Institute of Biological Products Co Ltd, H2 2020

Vaginal Cancer – Pipeline by Eisai Co Ltd, H2 2020

Vaginal Cancer – Pipeline by F. Hoffmann-La Roche Ltd, H2 2020

Vaginal Cancer – Pipeline by Fujifilm Holdings Corp, H2 2020

Vaginal Cancer – Pipeline by Gilead Sciences Inc, H2 2020

Vaginal Cancer – Pipeline by ISA Pharmaceuticals BV, H2 2020

Vaginal Cancer – Pipeline by Merck & Co Inc, H2 2020

Vaginal Cancer – Pipeline by Merck KGaA, H2 2020

Vaginal Cancer – Pipeline by Ology Bioservices Inc, H2 2020

Vaginal Cancer – Pipeline by Ono Pharmaceutical Co Ltd, H2 2020

Vaginal Cancer – Pipeline by PDS Biotechnology Corp, H2 2020

Vaginal Cancer – Pipeline by Plexxikon Inc, H2 2020

Vaginal Cancer – Pipeline by Precigen Inc, H2 2020

Vaginal Cancer – Pipeline by Shanghai Bovax Biotechnology Co Ltd, H2 2020

Vaginal Cancer – Pipeline by Shanghai Zerun Biotechnology Co Ltd, H2 2020

Vaginal Cancer – Pipeline by SQZ Biotechnologies Co, H2 2020

Vaginal Cancer – Pipeline by Transgene SA, H2 2020

Vaginal Cancer – Pipeline by Turnstone Biologics Inc, H2 2020

Vaginal Cancer – Dormant Projects, H2 2020

List of Figures

List of Figures

Number of Products under Development for Vaginal Cancer, H2 2020

Number of Products under Development by Companies, H2 2020

Number of Products by Top 10 Targets, H2 2020

Number of Products by Stage and Top 10 Targets, H2 2020

Number of Products by Top 10 Mechanism of Actions, H2 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020

Number of Products by Top 10 Routes of Administration, H2 2020

Number of Products by Stage and Top 10 Routes of Administration, H2 2020

Number of Products by Top 10 Molecule Types, H2 2020

Number of Products by Stage and Top 10 Molecule Types, H2 2020

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports